Evidence map›Paper›PMID 34905149›Full record

ArticleAdvances in therapy2022

The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases.

Juliana Setyawan, Emma Billmyer, Fan Mu, Andres Yarur, Miriam L Zichlin, Hongbo Yang, Nathaniel Downes, Nassir Azimi, Vibeke Strand

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Juliana SetyawanArena Pharmaceuticals, Inc., San Diego, CA, USA.
Emma BillmyerAnalysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Fan MuAnalysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA. Fan.Mu@analysisgroup.com.ORCID http://orcid.org/0000-0003-0252-0387
Andres YarurDivision of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA.
Miriam L ZichlinAnalysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Hongbo YangAnalysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Nathaniel DownesAnalysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Nassir AzimiSharp Grossmont Hospital, La Mesa, CA, USA.
Vibeke StrandDivision of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA.
Analysis Group (United States) · USArena Pharmaceuticals (United States) · USMedical College of Wisconsin · USSharp Grossmont Hospital · USStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThromboembolic events (TEs) are associated with considerable costs. However, there is a paucity of evidence quantifying the economic burden associated with TEs among patients with immune-mediated diseases (IMDs).

methodsThis retrospective cohort study used the IBM MarketScan

resultsOverall, 9681 matched patients were included in each cohort (mean age 61.1 years; 63.7% female). The TE cohort had higher proportions of comorbidities than the no TE cohort (Charlson Comorbidity Index [1.5 vs. 0.9]; p < 0.0001). Adjusted all-cause total healthcare costs were significantly greater in the TE cohort versus no TE cohort in the 30-day and 1-year periods following the index date (cost difference: 30-day, $17,574; 1-year, $36,459; both p < 0.0001) and were driven by inpatient costs (cost difference: 30-day, $14,864; 1-year, $23,360; both p < 0.0001). TE-related healthcare costs were $15,955 and $20,239 in the 30-day and 1-year periods, respectively.

conclusionAmong patients with IMDs, TEs are associated with substantial economic burden within 30-days and 1-year following the event.

Indexed as

Financial StressThromboembolismAdultAgedFemaleHealth Care CostsHumansMaleMedicareMiddle AgedRetrospective StudiesUnited StatesCostDeep vein thrombosisEconomic burdenImmune-mediated diseasesIschemic strokeMyocardial infarctionPulmonary embolismThromboembolic events

Identifiers

PMID34905149
PMCPMC8799558
OpenAlexW4200381077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.